203 related articles for article (PubMed ID: 18937434)
1. Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism.
Simoni D; Gebbia N; Invidiata FP; Eleopra M; Marchetti P; Rondanin R; Baruchello R; Provera S; Marchioro C; Tolomeo M; Marinelli L; Limongelli V; Novellino E; Kwaasi A; Dunford J; Buccheri S; Caccamo N; Dieli F
J Med Chem; 2008 Nov; 51(21):6800-7. PubMed ID: 18937434
[TBL] [Abstract][Full Text] [Related]
2. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Sanders JM; Ghosh S; Chan JM; Meints G; Wang H; Raker AM; Song Y; Colantino A; Burzynska A; Kafarski P; Morita CT; Oldfield E
J Med Chem; 2004 Jan; 47(2):375-84. PubMed ID: 14711309
[TBL] [Abstract][Full Text] [Related]
3. Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model.
Yuasa T; Sato K; Ashihara E; Takeuchi M; Maita S; Tsuchiya N; Habuchi T; Maekawa T; Kimura S
Cancer Immunol Immunother; 2009 Apr; 58(4):493-502. PubMed ID: 18682944
[TBL] [Abstract][Full Text] [Related]
4. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells.
Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F
Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982
[TBL] [Abstract][Full Text] [Related]
5. Defective gammadelta T-cell function and granzyme B gene polymorphism in a cohort of newly diagnosed breast cancer patients.
Gaafar A; Aljurf MD; Al-Sulaiman A; Iqniebi A; Manogaran PS; Mohamed GE; Al-Sayed A; Alzahrani H; Alsharif F; Mohareb F; Ajarim D; Tabakhi A; Al-Hussein K
Exp Hematol; 2009 Jul; 37(7):838-48. PubMed ID: 19446661
[TBL] [Abstract][Full Text] [Related]
6. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
Sanders JM; Song Y; Chan JM; Zhang Y; Jennings S; Kosztowski T; Odeh S; Flessner R; Schwerdtfeger C; Kotsikorou E; Meints GA; Gómez AO; González-Pacanowska D; Raker AM; Wang H; van Beek ER; Papapoulos SE; Morita CT; Oldfield E
J Med Chem; 2005 Apr; 48(8):2957-63. PubMed ID: 15828834
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class.
Clézardin P
Bone; 2011 Jan; 48(1):71-9. PubMed ID: 20655399
[TBL] [Abstract][Full Text] [Related]
8. Antitumor studies. Part 5: Synthesis, antitumor activity, and molecular docking study of 5-(monosubstituted amino)-2-deoxo-2-phenyl-5-deazaflavins.
Shrestha AR; Ali HI; Ashida N; Nagamatsu T
Bioorg Med Chem; 2008 Oct; 16(20):9161-70. PubMed ID: 18819815
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of dimethyl tin 4-cyclohexyl thiosemicarbazone as a novel antitumor agent.
Sen A; Chaudhuri TK
Exp Oncol; 2009 Mar; 31(1):22-6. PubMed ID: 19300412
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of a new class of aromatic bisphosphonates that inhibit tumor cell proliferation in vitro.
Guenin E; Ledoux D; Oudar O; Lecouvey M; Kraemer M
Anticancer Res; 2005; 25(2A):1139-45. PubMed ID: 15868957
[TBL] [Abstract][Full Text] [Related]
11. Comparison of phenotype of gammadelta T cells generated using various cultivation methods.
Mehrle S; Watzl C; von Lilienfeld-Toal M; Amoroso A; Schmidt J; Märten A
Immunol Lett; 2009 Jun; 125(1):53-8. PubMed ID: 19505505
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of gammadelta T cells reactive against cytomegalovirus-infected cells in a mouse xenograft tumor model.
Devaud C; Bilhere E; Loizon S; Pitard V; Behr C; Moreau JF; Dechanet-Merville J; Capone M
Cancer Res; 2009 May; 69(9):3971-8. PubMed ID: 19383918
[TBL] [Abstract][Full Text] [Related]
13. Repeated systemic administrations of both aminobisphosphonates and human Vγ9Vδ2 T cells efficiently control tumor development in vivo.
Santolaria T; Robard M; Léger A; Catros V; Bonneville M; Scotet E
J Immunol; 2013 Aug; 191(4):1993-2000. PubMed ID: 23836057
[TBL] [Abstract][Full Text] [Related]
14. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
15. Requirement of L-selectin for gammadelta T lymphocyte activation and migration during allergic pleurisy: co-relation with eosinophil accumulation.
Costa MF; Nihei J; Mengel J; Henriques MG; Penido C
Int Immunopharmacol; 2009 Mar; 9(3):303-12. PubMed ID: 19135179
[TBL] [Abstract][Full Text] [Related]
16. Perspectives of gammadelta T cells in tumor immunology.
Kabelitz D; Wesch D; He W
Cancer Res; 2007 Jan; 67(1):5-8. PubMed ID: 17210676
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and evaluation of novel kazusamycin A derivatives as potent antitumor agents.
Ando R; Amano Y; Nakamura H; Arai N; Kuwajima I
Bioorg Med Chem Lett; 2006 Jun; 16(12):3315-8. PubMed ID: 16617017
[TBL] [Abstract][Full Text] [Related]
18. Pyrrolo[1,5]benzoxa(thia)zepines as a new class of potent apoptotic agents. Biological studies and identification of an intracellular location of their drug target.
Mc Gee MM; Gemma S; Butini S; Ramunno A; Zisterer DM; Fattorusso C; Catalanotti B; Kukreja G; Fiorini I; Pisano C; Cucco C; Novellino E; Nacci V; Williams DC; Campiani G
J Med Chem; 2005 Jun; 48(13):4367-77. PubMed ID: 15974589
[TBL] [Abstract][Full Text] [Related]
19. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients.
Santini D; Martini F; Fratto ME; Galluzzo S; Vincenzi B; Agrati C; Turchi F; Piacentini P; Rocci L; Manavalan JS; Tonini G; Poccia F
Cancer Immunol Immunother; 2009 Jan; 58(1):31-8. PubMed ID: 18458903
[TBL] [Abstract][Full Text] [Related]
20. In vivo application of mAb directed against the gammadelta TCR does not deplete but generates "invisible" gammadelta T cells.
Koenecke C; Chennupati V; Schmitz S; Malissen B; Förster R; Prinz I
Eur J Immunol; 2009 Feb; 39(2):372-9. PubMed ID: 19130484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
